New insider activity at Neuphoria Therapeutics ( (NEUP) ) has taken place on October 23, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Significant shareholder Lynx1 Capital Management LP has made a notable investment by purchasing 639,110 shares of Neuphoria Therapeutics stock, valued at $3,278,634.
Recent Updates on NEUP stock
In the last 24 hours, Neuphoria Therapeutics experienced significant developments following the failure of its AFFIRM-1 Phase 3 trial for BNC210 in treating social anxiety disorder, which did not meet primary or secondary endpoints. This outcome led to the decision to discontinue the SAD program and prompted a strategic review of the company’s operations and portfolio. The trial’s failure resulted in a downgrade by Lucid Capital, citing the trial’s inability to achieve statistically significant results as a primary reason for the change in their outlook. Despite this setback, Neuphoria plans to focus on potential developments for BNC210 in PTSD and maintains its partnership with Merck for a Phase 2 trial in Alzheimer’s disease. The company’s cash position, reported at $14.2 million as of June 30, 2025, is expected to support operations through mid-2027.
More about Neuphoria Therapeutics
YTD Price Performance: 46.76%
Average Trading Volume: 125,767
Technical Sentiment Signal: Sell
Current Market Cap: $11.43M